Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avricore Health (AVCRF) Cash & Equivalents (2016 - 2025)

Avricore Health has reported Cash & Equivalents over the past 12 years, most recently at $812022.8 for Q4 2025.

  • Quarterly Cash & Equivalents changed 0.17% to $812022.8 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $812022.8 through Dec 2025, changed 0.17% year-over-year, with the annual reading at $810477.2 for FY2025, 2.01% down from the prior year.
  • Cash & Equivalents was $812022.8 for Q4 2025 at Avricore Health, up from $386389.6 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $2.0 million in Q1 2021 and troughed at $202212.3 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $727792.0 (2022), against an average of $851931.2.
  • Year-over-year, Cash & Equivalents skyrocketed 6079.41% in 2021 and then plummeted 71.37% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $1.6 million in 2021, then plummeted by 71.37% to $457144.1 in 2022, then decreased by 0.29% to $455799.1 in 2023, then soared by 77.85% to $810621.8 in 2024, then rose by 0.17% to $812022.8 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's Cash & Equivalents are $812022.8 (Q4 2025), $386389.6 (Q3 2025), and $817261.5 (Q2 2025).